{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:27:08Z","timestamp":1720744028502},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,11]]},"DOI":"10.7759\/cureus.64319","type":"journal-article","created":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T13:11:42Z","timestamp":1720703502000},"source":"Crossref","is-referenced-by-count":0,"title":["Nivolumab-Induced Diabetic Ketoacidosis: A Case Report"],"prefix":"10.7759","author":[{"given":"Drake","family":"Giese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Elkhedr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geethu","family":"Jnaneswaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine M","family":"Ernste","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas A","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018, 359:1350-5. 10.1126\/science.aar4060","journal-title":"Science"},{"key":"ref2","unstructured":"National Cancer Institute. https.\/\/www.cancer.gov\/about-cancer\/treatment\/drugs\/nivolumab#:~:text=(nih%2DVOL%2Dyoo%2D,from%20suppressing%20the%20...."},{"key":"ref3","unstructured":"Immune checkpoint inhibitors. https.\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/checkpoint-inhibitors."},{"key":"ref4","unstructured":"Immune checkpoint inhibitors and their side effects. https.\/\/www.cancer.org\/cancer\/managing-cancer\/treatment-types\/immunotherapy\/immune-checkpoint-inhibitors.html."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of Keynote-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck M","year":"2019","unstructured":"Reck M, Rodr\u00edguez-Abreu D, Robinson AG, et al.. Updated analysis of Keynote-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019, 37:537-46. 10.1200\/JCO.18.00149","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider BJ","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol. 2021, 39:4073-126. 10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa R","year":"2018","unstructured":"Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, Tolaney SM. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018, 4:173-82. 10.1001\/jamaoncol.2017.3064","journal-title":"JAMA Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220943949","article-title":"New onset diabetes with ketoacidosis following nivolumab immunotherapy: a case report and review of literature","volume":"27","author":"Delasos L","year":"2021","unstructured":"Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J. New onset diabetes with ketoacidosis following nivolumab immunotherapy: a case report and review of literature. J Oncol Pharm Pract. 2021, 27:716-21. 10.1177\/1078155220943949","journal-title":"J Oncol Pharm Pract"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli AM","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL, et al.. Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018, 67:1471-80. 10.2337\/dbi18-0002","journal-title":"Diabetes"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13424","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt Z","year":"2020","unstructured":"Quandt Z, Young A, Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020, 200:131-40. 10.1111\/cei.13424","journal-title":"Clin Exp Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette JM","year":"2019","unstructured":"de Filette JM, Pen JJ, Decoster L, et al.. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019, 181:363-74. 10.1530\/EJE-19-0291","journal-title":"Eur J Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15160","article-title":"Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors","volume":"38","author":"Qin Q","year":"2020","unstructured":"Qin Q, Patel VG, Wang B, et al.. Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors. J Clin Oncol. 2020, 38:15160-15160. 10.1200\/JCO.2020.38.15_suppl.e15160","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000480634","article-title":"Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management","volume":"10","author":"Kapke J","year":"2017","unstructured":"Kapke J, Shaheen Z, Kilari D, Knudson P, Wong S. Immune checkpoint inhibitor-associated type 1 diabetes mellitus: case series, review of the literature, and optimal management. Case Rep Oncol. 2017, 10:897-909. 10.1159\/000480634","journal-title":"Case Rep Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.4103\/sjmms.sjmms_478_19","article-title":"Management of diabetic ketoacidosis in adults: a narrative review","volume":"8","author":"Eledrisi MS","year":"2020","unstructured":"Eledrisi MS, Elzouki AN. Management of diabetic ketoacidosis in adults: a narrative review. Saudi J Med Med Sci. 2020, 8:165-73. 10.4103\/sjmms.sjmms_478_19","journal-title":"Saudi J Med Med Sci"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/268308-nivolumab-induced-diabetic-ketoacidosis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T13:11:46Z","timestamp":1720703506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/268308-nivolumab-induced-diabetic-ketoacidosis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,11]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.64319","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,11]]}}}